Lantus (Insulin Glargine) in Dano Health view
Insulin glargine with the trade name Lantus is a long-acting basal insulin analog that helps to control the blood sugar level of those with diabetes.
The medical name for Lantus is insulin glargine; it refers to the ways of modifying DNA of human insulin to form the analog.
It has been specifically designed to overcome the deficiencies of traditionally available ‘intermediate-acting’ insulins that are currently used for basal insulin supplementation.
According to the insulin glargine package insert, this medication consists of microcrystals that help to release insulin with a long duration of action (18 to 26 hours) with a “Peak-less” profile.
This drug is used to improve blood sugar control in adults and children with diabetes mellitus.
Lantus is used to treat
It may be used with a shorter-acting insulin product; it can be used alone or with other diabetes drugs.
Lantus in the long-acting class is considered a basal insulin that is administered once a day. Its duration of action is prolonged; there is no distinct insulin peak so that it is suitable for once-daily administration and reduce the risk of nocturnal hypoglycemia seen with intermediate-acting insulins.
Insulin glargine and natural human insulin work the same way, but Insulin glargine’s action lasts longer and helps diabetic patients regulate glucose or sugar in the body. It helps to promote movement of sugar from the blood into body tissues and also stops sugar production in the liver.
Lantus was manufactured by Sanofi-Aventis and has been available for pharmaceutical use since 2000.
The development of Lantus was conducted at Sanofi-Aventis’s biotechnology competence center in Frankfurt-Höchst. This company as the main Named-Patient drug distributor supplies the product to over 100 countries and more than 3,5 million patients worldwide; So this makes Lantus Germany’s largest and most important export pharmaceutical product. Dano Health as a Turkish pharmaceutical exporter also witnesses such the growth.
Lantus price is around $290 for a supply of 10 milliliters. Sanofi-Aventis increased its turn-over with Lantus around 28% to 2,45 Billion €, therefrom 130 Million € in Germany with approx. 1.8 million people with diabetes that use the product. It was the 15th highest selling pharmaceutical product in Germany in 2007. Lantus has led the way for years now, both in diabetes sales and in Sanofi sales and pumping out more than $7 billion worldwide for the company at its peak.
Since the patent on Lantus expired in 2015, other biosimilar versions of insulin glargine such as Toujeo by Sanofi and Basaglar by Lilly have been coming to market. Losing share to a biosimilar isn’t good for the top line and Since Toujeo launched in April 2015, So they tried hard to switch as many patients as possible over to the newer medication, in hopes of bridging its Lantus sales gap. But this new medication’s sales still pale in comparison to Lantus itself: €475 million in the U.S. last year, €630 million worldwide.
It’s appropriate to say that Dano Health as a clinical trial product distributor can provide Harvoni for the companies who looking for it, too.
With the slowdown in world economic growth, the industry of this medication has also suffered a certain impact, but still maintained a relatively optimistic growth during the past four years; the average annual growth rate of Insulin Glargine market was 7600 million $ in 2013 that increases to 8590 million $ in 2016. According to the BisReport analysts, Insulin Glargine market size will be further expanded slowdown during the next few years; they expect that by 2021, the market size of the Insulin Glargine will reach 9700 million $.